IQVIA Holdings Inc. (NYSE:IQV) Stake Lessened by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,375 shares of the medical research company’s stock after selling 1,279 shares during the period. IQVIA comprises about 3.2% of Washington Trust Advisors Inc.’s portfolio, making the stock its 7th largest holding. Washington Trust Advisors Inc. owned 0.08% of IQVIA worth $33,868,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. State Street Corp increased its stake in shares of IQVIA by 2.5% during the second quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock worth $1,899,660,000 after purchasing an additional 207,148 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of IQVIA by 19.1% during the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after acquiring an additional 952,850 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of IQVIA by 2.2% in the first quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock valued at $754,864,000 after acquiring an additional 81,501 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of IQVIA by 2.9% in the third quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after acquiring an additional 80,189 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of IQVIA by 3.4% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock worth $457,483,000 after purchasing an additional 77,422 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of several recent research reports. Barclays lifted their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Citigroup raised their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock a “neutral” rating in a research report on Monday, December 11th. Finally, Evercore ISI boosted their target price on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Stock Up 1.0 %

Shares of IQV traded up $2.56 during midday trading on Wednesday, hitting $250.30. The company had a trading volume of 346,459 shares, compared to its average volume of 1,024,068. The company’s 50-day simple moving average is $234.90 and its 200-day simple moving average is $217.29. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a market capitalization of $45.43 billion, a P/E ratio of 34.32, a P/E/G ratio of 2.41 and a beta of 1.51.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the previous year, the business posted $2.54 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the SEC, which is available at this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,285 shares of company stock valued at $10,331,003. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.